UY39297A - Compuestos y métodos para reducir la expresión de kcnt1 - Google Patents

Compuestos y métodos para reducir la expresión de kcnt1

Info

Publication number
UY39297A
UY39297A UY0001039297A UY39297A UY39297A UY 39297 A UY39297 A UY 39297A UY 0001039297 A UY0001039297 A UY 0001039297A UY 39297 A UY39297 A UY 39297A UY 39297 A UY39297 A UY 39297A
Authority
UY
Uruguay
Prior art keywords
compounds
methods
kcnt1
pharmaceutical compositions
expression
Prior art date
Application number
UY0001039297A
Other languages
English (en)
Spanish (es)
Inventor
Jafar-nejad Paymaan
Original Assignee
Ionis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionis Pharmaceuticals Inc filed Critical Ionis Pharmaceuticals Inc
Publication of UY39297A publication Critical patent/UY39297A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UY0001039297A 2020-06-25 2021-06-25 Compuestos y métodos para reducir la expresión de kcnt1 UY39297A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063044345P 2020-06-25 2020-06-25
US202063079438P 2020-09-16 2020-09-16

Publications (1)

Publication Number Publication Date
UY39297A true UY39297A (es) 2021-12-31

Family

ID=79281885

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039297A UY39297A (es) 2020-06-25 2021-06-25 Compuestos y métodos para reducir la expresión de kcnt1

Country Status (6)

Country Link
US (2) US20240229042A1 (cg-RX-API-DMAC10.html)
EP (1) EP4171576A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023533153A (cg-RX-API-DMAC10.html)
CN (1) CN115701998A (cg-RX-API-DMAC10.html)
UY (1) UY39297A (cg-RX-API-DMAC10.html)
WO (1) WO2021263082A2 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN122555695A (zh) * 2023-11-29 2026-08-11 爱克堤欧生物科学股份有限公司 可用作kcnt1抑制剂的杂环化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048787A1 (en) * 2000-06-14 2002-04-25 Ming-Hui Wei Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2005083127A2 (en) * 2004-02-27 2005-09-09 Applera Corporation Genetic polymorphisms associated with stroke, methods of detection and uses thereof
WO2018227247A1 (en) * 2017-06-13 2018-12-20 The Florey Institute Of Neuroscience And Mental Health Compositions and methods for treating conditions associated with gain-of-function mutations in kcnt1
JP2022515744A (ja) * 2018-12-20 2022-02-22 プラクシス プレシジョン メディシンズ, インコーポレイテッド Kcnt1関連障害の治療のための組成物及び方法

Also Published As

Publication number Publication date
WO2021263082A2 (en) 2021-12-30
WO2021263082A3 (en) 2022-02-10
US20260234639A1 (en) 2026-08-13
CN115701998A (zh) 2023-02-14
EP4171576A2 (en) 2023-05-03
JP2023533153A (ja) 2023-08-02
US20240229042A1 (en) 2024-07-11
EP4171576A4 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
CO2021013371A2 (es) Compuestos y métodos para reducir la expresión de kcnt1
CL2021002935A1 (es) Células t genomodificadas
CO2020015256A2 (es) Compuestos y métodos para la reducción de la expresión de lrrk2
CO2021012796A2 (es) Compuestos y métodos para modular ube3a-ats
BR112015014729A2 (pt) estrutura côncava, colheitadeira e método de processamento de uma cultura agrícola
UY38225A (es) Compuestos y métodos para reducir de la expresión de atxn3
ECSP24044340A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
CO2019003729A2 (es) Compuestos y métodos para reducir de la expresión de atxn3
CL2024000541A1 (es) Compuestos y métodos para modular el scn2a
DOP2011000114A (es) “compuestos de 9h-purin-6-aminoalquilo que expanden las celulas madre hematopoyeticas
MX2015010320A (es) Metodos y dietas para proteger contra la quimiotoxicidad y enfermedades asociadas con la edad.
CO6311007A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+, efectiva a dosis bajas
AR086493A1 (es) Malla metalica con indicador de elongacion y metodo para la determinacion de la elongacion de una malla metalica
MX2024002553A (es) Compuestos y metodos para modular la expresion de scn1a.
Haider Racial and ethnic infant mortality gaps and socioeconomic status
CL2025003288A1 (es) Anticuerpos que se unen a ox40l y métodos de uso.
CO2025007856A2 (es) Retención disminuida de miniproteínas en riñón
AR122744A1 (es) Compuestos y métodos para reducir la expresión de kcnt1
MX358639B (es) Sistema de mantenimiento para células reproductoras.
PE20220003A1 (es) Metodo para la prediccion de eficacia del tratamiento de hemoglobinopatia
WO2021263082A3 (en) Compounds and methods for reducing kcnt1 expression
EA202192527A1 (ru) Соединения и способы для снижения экспрессии kcnt1
Khan N-nitro-L-arginine, a nitric oxide synthase inhibitor, aggravates iminodipropionitrile-induced neurobehavioral and vestibular toxicities in rats
Likhterman et al. Klinika i khirurgiya posledstviy cherepno-mozgovoy travmy
AR119686A1 (es) Compuestos y métodos para reducir la expresión de app

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20241010